Didier M E, Fischer S, Maki D G
Department of Medicine, University of Wisconsin Medical School, Madison, USA.
Blood Coagul Fibrinolysis. 1998 Apr;9(3):227-32. doi: 10.1097/00001721-199804000-00002.
Reconstituted recombinant factor VIII (FVIIIrec) loses little biologic activity at room temperature for up to seven days and continuous infusion is convenient, effective hemostatically and requires less FVIIIrec concentrate than treatment by conventional bolus injections. However, the potential for bacterial contamination, with proliferation to high levels that can cause bacteremia, is a concern with continuous infusion. We studied the growth properties at 4, 25 and 35 degrees C in reconstituted FVIIIrec (Kogenate) and at 25 degrees C in 5% dextrose in water (D5%W) of three isolates each of Staphylococcus epidermidis, Staphylococcus aureus, Enterobacter cloacae, Klebsiella oxytoca, Serratia marcescens, Acinetobacter calcoaceticus, Stenotrophomonas maltophilia, Pseudomonas aeruginosa, Burkholderia cepacia, Flavobacterium spp. and Candida albicans, species most likely to contaminate infusate during preparation or administration and which have been implicated in more than 95% of all outbreaks and sporadic cases of nosocomial bloodstream infection traced to contaminated admixtures, biologic agents or medications administered parenterally. Reconstituted FVIIIrec allowed growth of only three species at 25 degrees C and 35 degrees C: S. marcescens, S. maltophilia and P. aeruginosa; logarithmic growth appeared only after 24-48 h. D5%W allowed growth of two gram-negative species, S. marcescens and B. cepacia. We conclude that reconstituted FVIIIrec (Kogenate) is a poor growth medium for most nosocomial pathogens, comparable with D5%W. If reconstituted aseptically, continuous infusion of reconstituted FVIIIrec should be safe, and it should not be necessary to replace the container or tubing more frequently than every 3 days, an administration schedule that can provide effective hemostasis at lower cost.
重组凝血因子VIII(FVIIIrec)在室温下长达7天几乎不丧失生物活性,持续输注方便、止血效果好,且与传统大剂量注射治疗相比所需的FVIIIrec浓缩物更少。然而,持续输注存在细菌污染的可能性,细菌大量繁殖可导致菌血症,这是一个令人担忧的问题。我们研究了表皮葡萄球菌、金黄色葡萄球菌、阴沟肠杆菌、产酸克雷伯菌、粘质沙雷氏菌、醋酸钙不动杆菌、嗜麦芽窄食单胞菌、铜绿假单胞菌、洋葱伯克霍尔德菌、黄杆菌属和白色念珠菌这三种分离株在重组FVIIIrec(科跃奇)中于4℃、25℃和35℃以及在5%葡萄糖水溶液(D5%W)中于25℃的生长特性,这些菌种最有可能在制剂制备或给药过程中污染输注液,并且在所有追溯到污染的混合液、生物制剂或胃肠外给药的医院血流感染暴发和散发病例中,超过95%都与之有关。重组FVIIIrec仅允许三种菌种在25℃和35℃生长:粘质沙雷氏菌、嗜麦芽窄食单胞菌和铜绿假单胞菌;对数生长期仅在24 - 48小时后出现。D5%W允许两种革兰氏阴性菌种生长,即粘质沙雷氏菌和洋葱伯克霍尔德菌。我们得出结论,重组FVIIIrec(科跃奇)对大多数医院病原体而言是一种不良生长培养基,与D5%W相当。如果无菌重组,重组FVIIIrec的持续输注应该是安全的,并且没有必要比每3天更频繁地更换容器或管路,这样的给药方案能够以更低成本提供有效的止血效果。